EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer

Naomi Kiyota iD, Makoto Tahara iD, Hiroo Imai, Shunji Takahashi, Akihiro Nishiyama, Shingo Tamura, Yasushi Shimizu, Shigenori Kadowaki, Ken-Ichi Ito, Yoshinori Hirashima, Shinji Ueno, Iwao Sugitani iD

European Thyroid Journal · 01.04.2026 · 15 (2)

DOI: 10.1530/etj-25-0273 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Thyroid Journal, online erschienen am 23.03.2026. Verfasst von Naomi Kiyota und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan. Hauptthemen laut MEDLINE: Carbamates, Sulfonamides, Quality of Life, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A Japanese phase 2 trial of encorafenib plus binimetinib met the primary endpoint of the centrally assessed objective response rate in patients with unresectable BRAF V600E-mutated thyroid cancer. Consequently, encorafenib plus binimetinib has been approved in Japan. We present the health-related quality of life (HR-QoL) outcomes from the trial.

Methods

The multicenter, open-label, uncontrolled phase 2 trial enrolled patients with unresectable locally advanced or metastatic BRAF V600E-mutated thyroid cancer. HR-QoL score, one of the secondary endpoints, was assessed using the EORTC QLQ-C30 and QLQ-THY34 at baseline and during follow-up. The minimal important change (MIC) threshold was set at 10 points.

Results

We enrolled 22 patients with BRAF V600E-mutated thyroid cancer. The median follow-up was 11.5 months. Completion rates for the questionnaires were 100% (22 of 22 patients) at baseline and 68% (15 of 22) at week 20. Until week 20, changes from baseline were below MIC at most time points in 29 of all 32 domains in QLQ-C30 and QLQ-THY34. In the other 3 domains, patients showed tendencies toward improvement (social support and appetite loss) or deterioration (joint pain) for consecutive time points. Patients with anaplastic thyroid cancer showed tendencies toward improvement for swallowing, restlessness, body image, and discomfort in the head and neck, from the first assessment after the initial treatment.

Conclusion

The combination therapy of encorafenib plus binimetinib for unresectable BRAF V600E-mutated thyroid cancer was associated with generally maintained HR-QoL. Considering the efficacy and safety data from the trial, the regimen may provide clinical benefits while maintaining HR-QoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarbamatesSulfonamidesQuality of LifeProto-Oncogene Proteins B-rafBenzimidazolesThyroid NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMaleMiddle AgedAgedMutationAdult

Stichwörter der Autor:innen

BRAF V600Ea BRAF inhibitora MEK inhibitoranaplastic thyroid cancerdifferentiated thyroid cancerhealth-related quality of lifemultitargeted tyrosine kinase inhibitors (MKIs)patient-reported outcomethyroid cancer

Substanzen

encorafenibCarbamatesbinimetinibSulfonamidesProto-Oncogene Proteins B-rafBenzimidazolesBRAF protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, Hyogo, Japan.
  • Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
  • Department of Medical Oncology, Tohoku University Hospital, Sendai, Miyagi, Japan.
  • Department of Medical Oncology, The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan.
  • Department of Medical Oncology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
  • Department of Medical Oncology, NHO Kyushu Medical Center, Fukuoka, Fukuoka, Japan.

ORCID-Profile: Naomi Kiyota, Makoto Tahara, Iwao Sugitani

Zitieren

APA

Kiyota, N., Tahara, M., Imai, H., Takahashi, S., Nishiyama, A., Tamura, S., Shimizu, Y., Kadowaki, S., Ito, K. I., Hirashima, Y., Ueno, S., & Sugitani, I. (2026). Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer. European Thyroid Journal, 15(2). https://doi.org/10.1530/etj-25-0273

Vancouver

Kiyota N, Tahara M, Imai H, Takahashi S, Nishiyama A, Tamura S, et al. Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer. European Thyroid Journal. 2026;15(2). doi:10.1530/etj-25-0273

BibTeX
@article{Kiyota2026,
  author = {Kiyota, Naomi and Tahara, Makoto and Imai, Hiroo and Takahashi, Shunji and Nishiyama, Akihiro and Tamura, Shingo and Shimizu, Yasushi and Kadowaki, Shigenori and Ito, Ken-Ichi and Hirashima, Yoshinori and Ueno, Shinji and Sugitani, Iwao},
  title = {Health-related quality of life with encorafenib plus binimetinib for BRAF V600E thyroid cancer},
  journal = {European Thyroid Journal},
  year = {2026},
  volume = {15},
  number = {2},
  doi = {10.1530/etj-25-0273}
}
Kostenlos starten →